Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Patient perceptions of multiple sclerosis and its treatment.
COMPARE: pharmacokinetic profiles of subcutaneous peginterferon beta-1a and subcutaneous interferon beta-1a over 2 weeks in healthy subjects.
Proton Density MRI Increases Detection of Cervical Spinal Cord Multiple Sclerosis Lesions Compared with T2-Weighted Fast Spin-Echo.
High-dose cyclophosphamide in multiple sclerosis patients undergoing autologous stem cell transplantation.
Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study.
Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis.
PLEGRIDY™ (peginterferon beta-1a) two-year data confirm maintenance of efficacy and safety in multiple sclerosis patients
Mesenchymal stem cells protect CNS neurons against glutamate excitotoxicity by inhibiting glutamate receptor expression and function.
Multiple sclerosis symptom recrudescence at the end of the natalizumab dosing cycle.
Minocycline treatment for rheumatoid arthritis: an open dose finding study.
Corpus Callosum Atrophy - A Simple Predictor of Multiple Sclerosis Progression: A Longitudinal 9-Year Study.
Platelets provide a bounty of potential targets for therapy in multiple sclerosis.
Rush University Medical Center Sells AMPYRA® Royalty Rights to DRI Capital Managed Fund for Approximately $42 Million
High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis.
Placebo? no thanks, it might be bad for me!
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Incidence of Mood or Anxiety Disorders in Children of Parents with Multiple Sclerosis.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Celgene to Acquire Receptos, Advancing Leadership in Immune-Inflammatory Diseases
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesis.
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis.
Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives.

Pages